Ranbaxy
Laboratories and US drugmaker Teva have jointly agreed to settle an
investigation launched by the New York Attorney General alleging the two
rival generic drug makers made an unlawful agreement to restrict
competition. As part of the settlement of the claim, the companies will
terminate an agreement not to challenge each other’s rights to sell
certain generic drugs exclusively in the US and also agreed to refrain
from entering into similar agreements in the future, besides paying a
penalty of $300,000.For more information ✆ - 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment